LONDON (Alliance News) - Avacta Group PLC on Monday said it has selected a clinical development candidate AVA004 for first-time-in-human clinical trials of its Affimer platform.Affimer an a Read More
LONDON (Alliance News) - Avacta Group PLC on Monday said it is planning to submit an application to test its TMAC linker in patients with selected solid tumours in early 2020.The company, a Read More
LONDON (Alliance News) - Avacta Group PLC on Tuesday reported a widened first half loss mainly due to lower income contribution from life sciences unit.The stock was trading 8.5% lower on a Read More
